Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

@article{Maliepaard2001CircumventionOB,
  title={Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.},
  author={Marc Maliepaard and Marg{\^o}t A van Gastelen and Akiko Tohgo and Frederick H. Hausheer and Robert C A M van Waardenburg and Laurina A. de Jong and Dick Pluim and Jos H. Beijnen and Jan H. M. Schellens},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2001},
  volume={7 4},
  pages={935-41}
}

• Marc Maliepaard, Margôt A van Gastelen, +6 authors Jan H. M. Schellens
• Published 2001 in
  Clinical cancer research : an official journal of…

This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF120918. Camptothecins studied were topotecan, CPT-11, and its active metabolite SN-38, 9-aminocamptothecin, and the novel experimental camptothecins NX211, DX8951f, and BNP1350. Notably, DX8951f and BNP1350 appeared to be very poor substrates for BCRP… CONTINUE READING

Save to Library

Create Alert

Cite

View Paper